The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
2017 U.S. ASPIRE Hemophilia Research Awards Program
The 2017 U.S. Advancing Science through Pfizer: Investigator Research Exchange (ASPIRE) Hemophilia Research Awards Program is a competitive grants program that reflects the commitment of Pfizer Hemophilia to support ongoing basic science and clinical investigation in hemophilia A and B.
Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for hemophilia A and hemophilia B and their related comorbidities. In an era of increased competition for research funding, the 2017 U.S. ASPIRE Hemophilia Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of hemophilia A and B.
- To advance basic science, translational and clinical research through a competitive grants program that increases medical knowledge in the pathogenesis, complications, management, and clinical outcomes of hemophilia A and B.
- To support academic research as well as the career development of promising young and established scientists.
Deadline: Mar. 31, 2017
To be eligible:
- The study must take place entirely in the US, and all sites must be located in the US. The Principle Investigator (PI) and sponsoring organization must be located in the United States.
- The applicant (PI) must have a medical degree (MD or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
Note: Current external review panel members are not eligible to apply, either as applicant or co-applicant. Serving as a mentor, however, to an applicant is permitted